Related references
Note: Only part of the references are listed.Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs
Domenico Pastore et al.
ANNALS OF HEMATOLOGY (2020)
The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus
Jakob R. Passweg et al.
BONE MARROW TRANSPLANTATION (2020)
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
Anita D'Souza et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
Nicola Di Renzo et al.
BONE MARROW TRANSPLANTATION (2020)
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
Vincenzo Apolito et al.
ANNALS OF HEMATOLOGY (2020)
BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition
Nunzio Del Gaudio et al.
CELL DEATH & DISEASE (2019)
ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients
Yasmeen Razvi et al.
SUPPORTIVE CARE IN CANCER (2019)
Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2019)
The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia
Antonella Di Costanzo et al.
ONCOGENE (2018)
Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey
Matti Aapro et al.
CANCER REPORTS (2018)
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study
Atsushi Isoda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study
Steven Trifilio et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
G. Dranitsaris et al.
ANNALS OF ONCOLOGY (2017)
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant
Stephen Michael Clark et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2014)
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy
Aurora Mirabile et al.
FUTURE ONCOLOGY (2014)
Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial
Thomas Schmitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study
Thomas Bechtel et al.
SUPPORTIVE CARE IN CANCER (2014)
Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study
Delva Deauna-Limayo et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Effectiveness and Safety of Antiemetic Aprepitant in Japanese Patients Receiving High-Dose Chemotherapy Prior to Autologous Hematopoietic Stem Cell Transplantation
Mayako Uchida et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2013)
Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
Ulas D. Bayraktar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma
Massimo Martino et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
The p63 Protein Isoform ΔNp63α Modulates Y-box Binding Protein 1 in Its Subcellular Distribution and Regulation of Cell Survival and Motility Genes
Antonella Di Costanzo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Electrocardiographic findings of palonosetron in cancer patients
Guzin Gonullu et al.
SUPPORTIVE CARE IN CANCER (2012)
Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant
Andrea Tendas et al.
SUPPORTIVE CARE IN CANCER (2012)
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation
S. A. Giralt et al.
ANNALS OF ONCOLOGY (2011)
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination
K. Jordan et al.
BONE MARROW TRANSPLANTATION (2011)
Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT
M. Musso et al.
BONE MARROW TRANSPLANTATION (2010)
200 mg/m(2) melphalan-the gold standard for multiple myeloma
Sergio Giralt
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Mechanisms of glucocorticoid-induced myopathy
O. Schakman et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell transplantation
J Larsen et al.
CANCER NURSING (2004)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
